ANI Pharmaceuticals declares FDA approval and commercialisation of Trimethoprim Tablets USP
16 November 2022 -

Bio-pharmaceutical company ANI Pharmaceuticals Inc (ANI or the Company) (Nasdaq: ANIP) reported on Wednesday that it has received US Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Trimethoprim Tablets USP, 100mg.

ANI said its Trimethoprim Tablets are the generic version of the Reference Listed Drug (RLD) of the same established name.

Nikhil Lalwani, president and chief executive officer of ANI, stated: "As we continue to focus on bringing niche limited-competition products to market, we are pleased to announce the FDA approval and commercialization of Trimethoprim Tablets."

ANI aims to serve patients in need by developing, manufacturing and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need.